Rifampin reduces concentrations of trimethoprim and sulfamethoxazole in serum in human immunodeficiency virus-infected patients

Antimicrob Agents Chemother. 2001 Nov;45(11):3238-41. doi: 10.1128/AAC.45.11.3238-3241.2001.

Abstract

To determine whether rifampin reduces concentrations of trimethoprim (TMP) and sulfamethoxazole (SMX) in serum of human immunodeficiency virus (HIV)-infected persons, levels of these agents were determined by high-performance liquid chromatography before and after more than 12 days of standard antituberculosis treatment for 10 patients who had been taking one double-strength tablet of co-trimoxazole once daily for more than 1 month. Statistically significant, 47 and 23% decreases in TMP and SMX mean areas under the concentration-time curve from 0 to 24 h (AUC(0-24)), respectively, were observed after administration of rifampin. N-Acetyl-SMX profiles without and with rifampin were similar. The steady-state AUC(0-24) metabolite/parent drug ratio increased by 32% with rifampin administration. Our study shows that rifampin reduces profiles of TMP and SMX in serum of HIV-infected patients.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Anti-Infective Agents / blood
  • Anti-Infective Agents / pharmacokinetics*
  • Antibiotics, Antitubercular / adverse effects*
  • Area Under Curve
  • Chromatography, High Pressure Liquid
  • Drug Interactions
  • Female
  • HIV Infections / metabolism*
  • Humans
  • Male
  • Rifampin / adverse effects*
  • Trimethoprim, Sulfamethoxazole Drug Combination / blood
  • Trimethoprim, Sulfamethoxazole Drug Combination / pharmacokinetics*

Substances

  • Anti-Infective Agents
  • Antibiotics, Antitubercular
  • Trimethoprim, Sulfamethoxazole Drug Combination
  • Rifampin